Get the Stockscreener App
1.25
0.79%
-0.01
After Hours:
1.25
Celularity Inc stock is traded at $1.25, with a volume of 29,442.
It is down -0.79% in the last 24 hours and down -36.87% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$1.26
Open:
$1.31
24h Volume:
29,442
Relative Volume:
0.29
Market Cap:
$36.05M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-0.7975
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
+11.11%
1M Performance:
-36.87%
6M Performance:
-36.87%
1Y Performance:
-44.69%
1-Day Range:
$1.20
$1.31
1-Week Range:
$1.01
$1.31
52-Week Range:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.25 | 36.34M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Does Shoora Designs Limited Stock Fit a LongTerm Value StrategyMarket Rumors and News & High Return Stock Ideas - earlytimes.in
Sheppard Mullin Advised Vanterra Ventures, Silo Pharma, Celularity And Others In Recent Deals - Mondaq
Celularity files for offering of up to 14.1 million shares of class A common stock - marketscreener.com
Celularity Files for Sale of 14.1 Million Class A Shares - marketscreener.com
Celularity (NASDAQ:CELU) Trading Down 10.4% – Here’s Why - Defense World
Celularity's Biovance, Biovance 3L To Remain Eligible For Med. Coverage Under Withdrawn LCDs - Nasdaq
Aug Outlook: What Wall Street predicts for Celularity Inc Equity Warrant stock price2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - moha.gov.vn
Celularity secures new financing to support strategic shift - MSN
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations - Investing News Network
Celularity stock drops after CMS withdraws skin substitute LCDs By Investing.com - Investing.com Nigeria
Celularity stock drops after CMS withdraws skin substitute LCDs - Investing.com
Celularity Inc. Comments on CMS Withdrawal of Skin Substitute Coverage Determinations - Quiver Quantitative
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations - The Manila Times
Medicare rewrites rules for wound skin grafts; Celularity says it’s ready - Stock Titan
Celularity Secures New Financing To Support Strategic Shift - The Globe and Mail
Celularity Signs Multiple Material Agreements - TradingView — Track All Markets
Celularity Closes Financing Transactions - citybiz
Celularity secures $10 million financing from DoubleLine co-founder By Investing.com - Investing.com Nigeria
Celularity Announces Closing of Financing Transactions - Investing News Network
Celularity secures $10 million financing from DoubleLine co-founder - Investing.com India
Longevity-focused biotech Celularity raises $10M for aging research - Stock Titan
Celularity announces up to $12M of capital from Philip Barach - MSN
Is Celularity Inc. Equity Warrant stock a smart buy before Fed meetingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - bolumsonucanavari.com
Why Celularity Inc. Equity Warrant stock could rally in 20252025 Price Action Summary & Verified Swing Trading Watchlist - DonanımHaber
Celularity Shareholders Reject Expansion of Equity Incentive Plan - The Globe and Mail
Can Celularity Inc. stock deliver surprise earnings beatJuly 2025 Earnings & AI Enhanced Trading Alerts - Улправда
Will Celularity Inc. stock outperform tech sector in 20252025 Volatility Report & Free High Accuracy Swing Entry Alerts - Улправда
Why Celularity Inc. Equity Warrant stock could benefit from AI revolution2025 Stock Rankings & Safe Investment Capital Preservation Plans - Улправда
Celularity raises $12m to sharpen longevity strategy - Longevity.Technology
What Wall Street predicts for Celularity Inc. Equity Warrant stock priceAnalyst Downgrade & Real-Time Sentiment Analysis - DonanımHaber
Is Celularity Inc. Equity Warrant stock dividend yield sustainable2025 Market Outlook & AI Based Buy and Sell Signals - DonanımHaber
Why Celularity Inc. stock is favored by top institutionsStop Loss & Weekly Watchlist for Hot Stocks - DonanımHaber
Will Celularity Inc. Equity Warrant stock outperform Dow Jones indexPortfolio Risk Report & Risk Controlled Swing Alerts - DonanımHaber
Performance Recap: Will Celularity Inc. stock outperform tech sector in 2025Weekly Trade Summary & Growth Focused Stock Reports - moha.gov.vn
Why Celularity Inc. stock is favored by pension funds2025 Risk Factors & Precise Buy Zone Identification - Улправда
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision - Investing News Network
Celularity secures up to $12 million in financing for longevity focus - Investing.com Australia
Celularity Inc. Secures Up to $12 Million in Financing to Advance Strategic Priorities in Longevity and Human Performance - Quiver Quantitative
DoubleLine co-founder backs up to $12M funding plan for longevity - Stock Titan
Celularity Inc.'s (NASDAQ:CELU) 25% Dip In Price Shows Sentiment Is Matching Revenues - 富途牛牛
Celularity Inc. announced that it expects to receive $12 million in funding - marketscreener.com
There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding - simplywall.st
Celularity Inc. (GXGXW) Fundamental Analysis - Meyka
Celularity Inc. (CELU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Outlook: Why Celularity Inc Equity Warrant stock is considered a top pickWeekly Trade Summary & Weekly Chart Analysis and Guides - moha.gov.vn
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hariri Robert J | Chief Executive Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
3,281 |
0 |
21,482 |
| Haines John R | Senior Exec Vice President |
Apr 13 '25 |
Option Exercise |
0.00 |
1,641 |
0 |
29,698 |
| Beers David C | Chief Financial Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
1,025 |
0 |
18,561 |
| Brigido Stephen | Pres., Functional Regeneration |
Feb 17 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
11,641 |
| Beers David C | Chief Financial Officer |
Feb 17 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
21,932 |
| Haines John R | Senior Exec Vice President |
Feb 17 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
35,092 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):